A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Sunday, May 17, 2026 9:32 AM to 9:40 AM · 8 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail
Oncology: Bladder

Registered attendees

Beatriz Hernandez
Beatriz Hernandez
Research FellowshipBaylor College of Medicine
Seth Lerner
Seth Lerner
Vice Chair for Faculty AffairsBaylor College of Medicine Scott Department of Urology
Yakov Klugman
Yakov Klugman
Medical StudentRoswell Park Comprehensive Cancer Center

Log in

See all the content and easy-to-use features by logging in or registering!